sprite-preloader
Anzeige
Mehr »
Freitag, 19.10.2018 Börsentäglich über 12.000 News von 596 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: 897518 ISIN: US62855J1043 Ticker-Symbol: MYD 
Aktie:
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
S&P SmallCap 600
1-Jahres-Chart
MYRIAD GENETICS INC Chart 1 Jahr
1-Woche-Intraday-Chart
MYRIAD GENETICS INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
38,678
39,262
18.10.
38,70
39,16
18.10.
17.05.2018 | 21:44
(8 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / May 17, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc. (NASDAQ: MYGN) who purchased shares between August 13, 2014 and March 12, 2018. The action, which was filed in the United States District Court for the District of Utah, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company's hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad's revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad's public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning "an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid."

Shareholders have until June 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/myriad-genetics-inc?wire=1.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


© 2018 ACCESSWIRE